

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : C12N 15/86, 15/45, C07K 14/135, 14/115, A61K 31/70</p>	<p>A1</p>	<p>(11) International Publication Number: <b>WO 99/25858</b>  (43) International Publication Date: 27 May 1999 (27.05.99)</p>
<p>(21) International Application Number: PCT/CA98/01064  (22) International Filing Date: 13 November 1998 (13.11.98)  (30) Priority Data: 60/065,791 14 November 1997 (14.11.97) US  (71) Applicant (for all designated States except US): CONNAUGHT LABORATORIES LIMITED [CA/CA]; 1755 Steeles Av- enue West, North York, Ontario M2R 3T4 (CA).  (72) Inventors; and (75) Inventors/Applicants (for US only): PARRINGTON, Mark [CA/CA]; 45 Martin Street, Bradford, Ontario L3Z 1Z4 (CA). LI, Xiaomao [CN/CA]; 106 Glenmanor Way, Thorn- hill, Ontario L4J 3E5 (CA).  (74) Agent: STEWART, Michael, I.; 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: ALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES</p> <p>(57) Abstract</p> <p>A DNA vector comprises a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, and a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter, preferably a cytomegalovirus promoter, which may include Intron A. Such vectors also contain a further nucleotide sequence located between the promoter sequence and the alphavirus sequence to enhance the immunoprotective ability of the RSV F protein when expressed <i>in vivo</i>. Such DNA vectors may be used to immunize a host against disease caused by infection with RSV or other paramyxovirus, including a human host, by administration thereto, and may be formulated as immunogenic compositions with pharmaceutically-acceptable carriers for such purposes. Such vectors also may be used to produce antibodies for detection of RSV or other paramyxovirus infection in a sample.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF INVENTIONALPHAVIRUS VECTORS FOR PARAMYXOVIRUS VACCINES

5

FIELD OF INVENTION

The present invention relates to the field of paramyxoviridae vaccines and is particularly concerned with vaccines comprising DNA encoding the fusion (F) protein of respiratory syncytial virus (RSV) in an alphavirus vector.

BACKGROUND OF THE INVENTION

Human respiratory syncytial virus (RSV) has been identified as a major pathogen responsible for severe respiratory tract infections in infants, young children and the institutionalized elderly (refs. 1,2,3,4 - throughout this application, various references are cited in parentheses to describe more fully the state of the art to which this invention pertains. Full bibliographic information for each citation is found at the end of the specification, immediately preceding the claims. The disclosures of these references are hereby incorporated by reference into the present disclosure). Global mortality and morbidity figures indicate that there is an urgent need for an efficacious RSV vaccine (refs. 5,6). In the USA alone, approximately 100,000 children are hospitalized annually with severe cases of pneumonia and bronchiolitis resulting from an RSV infection. Inpatient and ambulatory care for children with RSV infections has been estimated to cost in excess of \$340 million each year in the USA. The World Health Organization (WHO) and the National Institute of Allergy and Infectious Disease (NIAID) vaccine advisory

committees have ranked RSV second only to HIV for vaccine development. Both the annual morbidity and mortality figures as well as the staggering health care costs for managing RSV infections have provided the  
5 incentive for aggressively pursuing the development of efficacious RSV vaccines. However, such a vaccine is still not available.

Formalin-inactivated (FI-RSV) and live attenuated RSV vaccines have failed to demonstrate efficacy in  
10 clinical trials (refs. 7,8,9,10). Moreover, the formalin-inactivated RSV vaccine caused enhanced disease in some children following exposure to wild-type RSV (refs. 7,8,9,10). Elucidation of the mechanism(s) involved in the potentiation of RSV disease is important  
15 for the design of safe RSV vaccines, especially for the seronegative population. Recent experimental evidence suggests that an imbalance in cell-mediated responses may contribute to immunopotential. Enhanced histopathology observed in mice that were immunized with  
20 the FI-RSV and challenged with virus could be abrogated by depletion of CD4+ cells or both interleukin-4 (IL-4) and IL-10.

The RSV fusion (F) glycoprotein is one of the major immunogenic proteins of the virus. This envelope  
25 glycoprotein mediates both fusion of the virus to the host cell membrane and cell-to-cell spread of the virus (ref. 1). The F protein is synthesized as a precursor (F<sub>0</sub>) molecule which is proteolytically cleaved to form a disulphide-linked dimer composed of the N-terminal F<sub>2</sub>  
30 and C-terminal F<sub>1</sub> moieties (ref. 11). The amino acid sequence of the F protein is highly conserved among RSV

subgroups A and B and is a cross-protective antigen (refs. 6,12). In the baculovirus expression system, a truncated secreted version of the RSV F protein has been expressed in *Trichoplusia ni* insect cells (ref. 13). The  
5 recombinant protein was demonstrated to be protective in the cotton rats (ref. 13).

Studies on the development of live viral vaccines and glycoprotein subunit vaccines against parainfluenza virus infection are being pursued. Clinical trial  
10 results with a formalin-inactivated PIV types 1,2,3 vaccine demonstrated that this vaccine was not efficacious (refs. 14, 15, 16). Further development of chemically-inactivated vaccines was discontinued after clinical trials with a formalin-inactivated RSV vaccine  
15 demonstrated that not only was the vaccine not effective in preventing RSV infection but many of the vaccinees who later become infected with RSV suffered a more serious disease. Most of parainfluenza vaccine research has focused on candidate PIV-3 vaccines (ref. 17) with  
20 significantly less work being reported for PIV-1 and PIV-2. Recent approaches to PIV-3 vaccines have included the use of the closely related bovine parainfluenza virus type 3 and the generation of attenuated viruses by cold-adaptation of the virus  
25 (refs. 18, 19, 20, 21).

Another approach to parainfluenza virus type 3 vaccine development is a subunit approach focusing on the surface glycoproteins hemagglutinin-neuraminidase (HN) and the fusion (F) protein (refs. 22, 23, 24). The  
30 HN antigen, a typical type II glycoprotein, exhibits both haemagglutination and neuraminidase activities and

is responsible for the attachment of the virus to sialic acid containing host cell receptors. The type I F glycoprotein mediates fusion of the viral envelope with the cell membrane as well as cell to cell spread of the virus. It has recently been demonstrated that both the HN and F glycoproteins are required for membrane fusion. The F glycoprotein is synthesized as an inactive precursor (F) which is proteolytically cleaved into disulfide-linked F2 and F1 moieties. While the HN and F proteins of PIV-1, -2 and -3 are structurally similar, they are antigenically distinct. Neutralizing antibodies against the HN and F proteins of one of PIV type are not cross-protective. Thus, an effective PIV subunit vaccine must contain the HN and F glycoproteins from the three different types of parainfluenza viruses. Antibody to either glycoprotein is neutralizing in vitro. A direct correlation has been observed between the level of neutralizing antibody titres and resistance to PIV-3 infections in infants. Native subunit vaccines for parainfluenza virus type 3 have investigated the protectiveness of the two surface glycoproteins. Typically, the glycoproteins are extracted from virus using non-ionic detergents and further purified using lectin affinity or immunoaffinity chromatographic methods. However, neither of these techniques may be entirely suitable for large scale production of vaccines under all circumstances. In small animal protection models (hamsters and cotton rats), immunization with the glycoproteins was demonstrated to prevent infection with live PIV-3 (refs. 25, 26, 27, 28, 29).

The HN and F glycoproteins of PIV-3 have also been produced using recombinant DNA technology. HN and F glycoproteins have been produced in insect cells using the baculovirus expression system and by use of vaccinia virus and adenovirus recombinants (refs. 30, 31, 32, 33, 34). In the baculovirus expression system, both full-length and truncated forms of the PIV-3 glycoproteins as well as a chimeric F-HN fusion protein have been expressed. The recombinant proteins have been demonstrated to be protective in small animal models (see WO91/00104, US Application No. 07/773,949 filed November 29, 1991, assigned to the assignee hereof).

Semliki Forest virus (SFV) is a member of the Alphavirus genus in the Togaviridae family. The mature virus particle contains a single copy of a ssRNA genome with a positive polarity that is 5'-capped and 3'-polyadenylated. It functions as an mRNA and naked RNA can start an infection when introduced into cells. Upon infection/transfection, the 5' two-thirds of the genome is translated into a polyprotein that is processed into the four nonstructural proteins (nsP1 to 4) by self cleavage. Once the ns proteins have been synthesized they are responsible for replicating the plus-strand (42S) genome into full-length minus strands (ref. 14). These minus-strands then serve as templates for the synthesis of new plus-strand (42S) genomes and the 26S subgenomic mRNA (ref. 14). This subgenomic mRNA, which is colinear with the last one-third of the genome, encodes the SFV structural proteins.

In 1991 Liljestrom and Garoff (ref. 15) designed a series of expression vectors based on the SFV cDNA



replicon. These vectors had the virus structural protein genes deleted to make the way for heterologous inserts, but preserved the nonstructural coding region for production of the nsP1 to 4 replicase complex.

- 5 Short 5' and 3' sequence elements required for RNA replication were also preserved. A polylinker site was inserted downstream from the 26S promoter followed by translation stop sites in all three frames. An SpeI site was inserted just after the 3' end of the SFV cDNA  
10 for linearization of the plasmid for use in vitro transcription reactions.

Injection of SFV RNA encoding a heterologous protein have been shown to result in the expression of the foreign protein and the induction of antibody in a  
15 number of studies (refs. 16,17). The use of SFV RNA inoculation to express foreign proteins for the purpose of immunization would have several of the advantages associated with plasmid DNA immunization. For example, SFV RNA encoding a viral antigen may be introduced in  
20 the presence of antibody to that virus without a loss in potency due to neutralization by antibodies to the virus. Also, because the protein is expressed in vivo the protein should have the same conformation as the protein expressed by the virus itself. Therefore,  
25 concerns about conformational changes which could occur during protein purification leading to a loss in immunogenicity, protective epitopes and possibly immunopotential, could be avoided by plasmid DNA immunization.

- 30 In copending US Patent Application No. 08/476,397 filed June 7, 1995, assigned to the assignee hereof and

the disclosure of which is incorporated herein by reference (WO96/040945), there is described reference the use of plasmid vectors containing RSV F protein-encoding DNA for DNA immunization against RSV infection.

- 5 In copending United States Patent Application No. 08/896,500 filed July 18, 1997, assigned to the assignee hereof and the disclosure of which is incorporated herein by reference, there is described the use of plasmid vectors containing RSV G protein-encoding DNA  
10 for DNA immunization against RSV infection.

In my copending United States Patent Application No. 08/923,558, filed September 4, 1997, assigned to the assignee hereof and the disclosure of which is incorporated by reference, I describe a DNA vector using  
15 an alphavirus vector, including Semliki Forest virus vector, containing a DNA sequence encoding a paramyxovirus protein, specifically RSV-F, for making an RNA transcript for immunization.

In WO95/27044, the disclosure of which is  
20 incorporated herein by reference, there is described the use of alphavirus cDNA vectors based on cDNA complementary to the alphavirus RNA sequence. Once transcribed from the cDNA under transcriptional control of a heterologous promoter, the alphavirus RNA is able  
25 to self-replicate by means of its own replicase and thereby amplify the copy number of the transcribed recombinant RNA molecules.

Infection with RSV leads to serious disease. It would be useful and desirable to provide improved  
30 vectors for *in vivo* administration of immunogenic preparations, including vaccines, for protection against

disease caused by RSV and other paramyxoviruses. In particular, it would be desirable to provide vaccines that are immunogenic and protective in humans, including seronegative infants, that do not cause disease enhancement (immunopotentialiation).

#### SUMMARY OF THE INVENTION

The present invention provides novel immunogenic materials and immunization procedures based on such novel materials for immunizing against disease caused by respiratory syncytial virus. In particular, the present invention is directed towards the provision of DNA vaccines against disease caused by infection with paramyxoviridae.

In accordance with one aspect of the present invention, there is provided a vector, comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit in vivo replication; a second DNA sequence encoding a paramyxovirus protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication; the first and second DNA sequences being under transcriptional control of a promoter; and a third DNA sequence located adjacent the second DNA sequence to enhance the immunoprotective ability of the paramyxovirus protein when expressed in vivo from the vector in a host.

The paramyxovirus protein may be selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial virus (RSV). The PIV protein may be from PIV-1, PIV-2, PIV-3 or PIV-4, particularly the  
5 HN and F glycoproteins of PIV-3. The RSV protein particularly may be the F or G glycoprotein of RSV.

The second DNA sequence may encode a full length RSV F protein, or may encode a RSV F protein lacking the transmembrane anchor and cytoplasmic tail. The  
10 lack of the coding region for the transmembrane anchor and cytoplasmic tail results in a secreted form of the RSV F protein. Alternatively, as described in the aforementioned U.S. Patent Application 08/896,500, the second DNA sequence may encode the full-length RSV-G  
15 protein or a truncated RSV G protein lacking a transmembrane region, resulting in a secreted form of the protein.

The alphavirus preferably is a Semliki Forest virus and the first DNA sequence is the Semliki Forest viral  
20 sequence contained in plasmid pSFVI.

The third nucleotide sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing, in vivo, whereby substantially all transcribed mRNA from the vector upon administration encodes the RSV protein.  
25 Such third nucleotide sequence is preferably located between the first nucleotide sequence and the promoter sequence. Such third nucleotide sequence may be that of rabbit  $\beta$ -globin intron II, as shown in Figure 8 of copending U.S. Patent Application No. 08/476,397 (WO  
30 96/040945).

10

The promoter sequence may be an immediate early cytomegalovirus (CMV) promoter. The human cytomegalovirus Intron A sequence may be provided downstream of the promoter and upstream of the third  
5 nucleotide sequence.

A vector encoding the F protein and provided in accordance with one embodiment of the invention may be specifically pMP44, having the identifying characteristics shown in Figure 1D.

10 The vectors provided herein may be used to immunize a host against RSV infection or disease by in vivo expression of RSV F protein or RSV G protein, which may lack a transmembrane region, or other paramyxovirus protein, following administration of the vectors. In  
15 accordance with a further aspect of the present invention, therefore, there is provided a method of immunizing a host against disease caused by infection with respiratory syncytial virus or other paramyxovirus, which comprises administering to the host an effective  
20 amount of a vector provided herein.

The present invention also includes a novel method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of generating antibodies which specifically react with RSV F or G  
25 protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises isolating the gene; operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the  
30 complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-

essential for replication to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; operatively linking the gene to an immunoprotection enhancing sequence to produce an enhanced immunoprotection by the RSV F or G protein in the host, preferably by introducing the immunoprotection enhancing sequence between the control sequence and the alphavirus sequence; and introducing the vector into the host. A corresponding procedure may be used for other paramyxoviridae.

In addition, the present invention includes a method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent; operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; operatively linking the first nucleotide sequence to a third nucleotide sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* from the vector in a host; and formulating the vector as a vaccine for *in vivo* administration. A corresponding procedure may be used for other paramyxoviridae.

The present invention further includes a vaccine for administration to a host, including a human host, produced by the method as well as immunogenic compositions comprising an immunoeffective amount of the  
5 vectors described herein.

#### BRIEF DESCRIPTION OF DRAWINGS

Figures 1A to 1B show a schematic of a procedure of assembly of vector pMP44;

Figures 2A to 2B show a schematic of a procedure of  
10 assembly of vector pMP44;

Figures 3A to 3E contain the nucleotide sequence of plasmid pMP44 (SEQ ID NO:1);

Figure 4 shows the anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after  
15 boosting;

Figure 5 shows the nucleotide sequence for a synthetic oligonucleotide coding for the hepatitis delta ribozyme (SEQ ID no; 2,3); and

Figures 6A to 6C show the nucleotide sequence for  
20 the SFV EcoRV-SpeI fragment ligated to the ribozyme of Figure 5 (SEQ ID no: 4).

GENERAL DESCRIPTION OF INVENTION

As described above, the present invention, in general, relates to protection of hosts against disease caused by infection by paramyxovirus by DNA immunization using DNA vectors. In particular, the invention is concerned with protection of hosts against disease caused by infection by respiratory syncytial virus (RSV), although not specifically limited thereto. The description which follows refers specifically to employing DNA sequences encoding RSV F or G protein and fragments thereof which generate antibodies which specifically react with RSV F or G protein.

In this application, the terms "RSV F protein" and "RSV G protein" are used to define a full-length RSV F or G protein, including proteins having variations in their amino acid sequences including those naturally occurring in various strain of RSV and those introduced by PCR amplification of the encoding gene while retaining the immunogenic properties, a secreted form of the RSV F or G protein lacking a transmembrane anchor and cytoplasmic tail, as well as fragments capable of generating antibodies which specifically react with RSV F or G protein and functional analogs. In this application, a first protein is a "functional analog" of a second protein if the first protein is immunologically related to and/or has the same function as the second protein. The functional analog may be, for example, a fragment of the protein or a substitution, addition or deletion mutant thereof.

A vector is constructed to contain a first DNA sequence which is complementary to at least part of an



alphavirus RNA genome, specifically Semliki Forest virus, and having the complement of complete alphavirus RNA genome replication regions to permit replication *in vivo*. A second DNA sequence encoding the RSV F or G protein is inserted into a region of the first DNA sequence which is non-essential for replication. The first and second DNA sequences are under transcriptional control of a promoter to permit expression of the RSV protein in a host immunized with the vector.

10 The promoter sequence may be the immediately early cytomegalovirus (CMV) promoter. This promoter is described in ref. 36. Any other convenient promoter may be used, including constitutive promoters, such as, Rous Sarcoma Virus LTRs, and inducible promoters, such as  
15 metallothionine promoter, and tissue specific promoters.

The recombinant vector may include a third nucleotide sequence located adjacent the alphavirus sequence to enhance the immunoprotective ability of the RSV F or G protein when expressed *in vivo* in a host.  
20 Such enhancement may be provided by increased *in vivo* expression, for example, by increased mRNA stability, enhanced transcription and/or translation. This additional sequence preferably is located between the promoter sequence and the alphavirus sequence.

25 This enhancement sequence may comprise a pair of splice sites to prevent aberrant mRNA splicing during transcription so that substantially all transcribed mRNA is intact alphavirus RNA encoding a gene of interest, for example, an RSV F protein. Specifically, rabbit  $\beta$ -globin Intron II sequence may provide such splice sites,  
30 as also described in ref. 37.

15

Additional enhancement may be obtained by, including an additional DNA sequence between the promoter and the enhancer sequence. Such additional DNA sequence may comprise the immediate early  
5 cytomegalovirus Intron A sequence.

The vectors provided herein, when administered to an animal, effect *in vivo* RSV F protein expression, as demonstrated by an antibody response in the animal to which it is administered and the conferring of  
10 protection. As may be seen from the results detailed in the Examples below, the DNA vectors produced a high anti-F IgG antibody titre and confer protection.

In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/476,397  
15 and 08/896,500, the vectors described herein provide a protective immune response using a lower dose and less time. In comparison to the vectors described in the aforementioned U.S. Patent Application nos. 08/923,558, 08/896,550 and 08/476,397 using native RSV F, the  
20 vectors described herein produce protective immune response in the absence of pretreatment of the animal model with cardiotoxin, a material known to increase the uptake of DNA and enhance the immune response.

The vector provided herein may also comprise a  
25 fourth nucleotide sequence encoding a further antigen from RSV, an antigen from at least one other pathogen or at least one immunomodulating agent, such as cytokine. Such vector may contain said fourth nucleotide sequence in a chimeric or a bicistronic structure. Alternatively,  
30 vectors containing the fourth nucleotide sequence may be

separately constructed and coadministered to a host, with the DNA vector provided herein.

In addition, there may be provided at the 3'-end of the Simliki Forest virus segment, a hepatitis delta virus ribosyme sequence to ensure proper *in vivo* cleavage at the 3'-end of the Simliki Forest virus sequence. Any other convenient sequence may be employed to achieve this effect.

It is clearly apparent to one skilled in the art, that the various embodiments of the present invention have many applications in the fields of vaccination, diagnosis and treatment of RSV infections. A further non-limiting discussion of such uses is further presented below.

#### 1. Vaccine Preparation and Use

Immunogenic compositions, suitable to be used as vaccines, may be prepared from the RSV F or RSV G genes and other paramyxovirus genes and vectors as disclosed herein. The vaccine elicits an immune response in a subject which includes the production of anti-F or anti-G antibodies. Immunogenic compositions, including vaccines, containing the DNA vector may be prepared as injectables, in physiologically-acceptable liquid solutions or emulsions for polynucleotide administration. The nucleic acid may be associated with liposomes, such as lecithin liposomes or other liposomes known in the art, as a nucleic acid liposome (for example, as described in WO 93/24640, ref. 38) or the DNA vector may be associated with an adjuvant, as described in more detail below. Liposomes comprising cationic lipids interact spontaneously and rapidly with

polyanions such as DNA and RNA, resulting in liposome/nucleic acid complexes that capture up to 100% of the polynucleotide. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotide that bypasses the degradative enzymes of the lysosomal compartment. Published PCT application WO 94/27435 describes compositions for genetic immunization comprising cationic lipids and polynucleotides. Agents which assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins and other transfection facilitating agents, may advantageously be used.

Polynucleotide immunogenic preparations may also be formulated as microcapsules, including biodegradable time-release particles. Thus, U.S. Patent 5,151,264 describes a particulate carrier of a phospholipid/glycolipid/polysaccharide nature that has been termed Bio Vecteurs Supra Moléculaires (BVSM). The particulate carriers are intended to transport a variety of molecules having biological activity in one of the layers thereof.

U.S. Patent 5,075,109 describes encapsulation of the antigens trinitrophenylated keyhole limpet hemocyanin and staphylococcal enterotoxin B in 50:50 poly (DL-lactide-co-glycolide). Other polymers for encapsulation are suggested, such as poly(glycolide), poly(DL-lactide-co-glycolide), copolyoxalates, polycaprolactone, poly(lactide-co-caprolactone), poly(esteramides), polyorthoesters and poly(8-hydroxybutyric acid), and polyanhydrides.

Published PCT application WO 91/06282 describes a delivery vehicle comprising a plurality of bioadhesive microspheres and antigens. The microspheres being of starch, gelatin, dextran, collagen or albumin. This  
5 delivery vehicle is particularly intended for the uptake of vaccine across the nasal mucosa. The delivery vehicle may additionally contain an absorption enhancer.

The RSV F or G genes and vectors may be mixed with pharmaceutically acceptable excipients which are  
10 compatible therewith. Such excipients may include, water, saline, dextrose, glycerol, ethanol, and combinations thereof. The immunogenic compositions and vaccines may further contain auxiliary substances, such as wetting or emulsifying agents, pH buffering agents,  
15 or adjuvants to enhance the effectiveness thereof. Immunogenic compositions and vaccines may be administered parenterally, by injection subcutaneously, intravenously, intradermally or intramuscularly, possibly following pretreatment of the injection site  
20 with a local anaesthetic. Alternatively, the immunogenic compositions formed according to the present invention, may be formulated and delivered in a manner to evoke an immune response at mucosal surfaces. Thus, the immunogenic composition may be administered to  
25 mucosal surfaces by, for example, the nasal or oral (intragastric) routes. Alternatively, other modes of administration including suppositories and oral formulations may be desirable. For suppositories, binders and carriers may include, for example,  
30 polyalkylene glycols or triglycerides. Oral formulations may include normally employed incipients,

such as, for example, pharmaceutical grades of saccharine, cellulose and magnesium carbonate.

The immunogenic preparations and vaccines are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective, protective and immunogenic. The quantity to be administered depends on the subject to be treated, including, for example, the capacity of the individual's immune system to synthesize the RSV F protein and antibodies thereto, and if needed, to produce a cell-mediated immune response. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. However, suitable dosage ranges are readily determinable by one skilled in the art and may be of the order of about 1  $\mu$ g to about 1 mg of the RSV F or G genes and vectors. Suitable regimes for initial administration and booster doses are also variable, but may include an initial administration followed by subsequent administrations. The dosage may also depend on the route of administration and will vary according to the size of the host. A vaccine which protects against only one pathogen is a monovalent vaccine. Vaccines which contain antigenic material of several pathogens are combined vaccines and also belong to the present invention. Such combined vaccines contain, for example, material from various pathogens or from various strains of the same pathogen, or from combinations of various pathogens.

In particular embodiments of the present invention, the vector comprising a first nucleotide sequence

encoding an F or G protein of RSV may be delivered in conjunction with a targeting molecule to target the vector to selected cells including cells of the immune system.

5       The DNA vectors may be delivered to the host by a variety of procedures, for example, Tang et al. (ref. 39) disclosed that introduction of gold microprojectiles coated with DNA encoding bovine growth hormone (BGH) into the skin of mice resulted in production of anti-BGH  
10       antibodies in the mice, while Furth et al. (ref. 40) showed that a jet injector could be used to transfect skin, muscle, fat and mammary tissues of living animals.

## 2.    **Immunoassays**

      The RSV F or G genes and vectors of the present  
15       invention are useful as immunogens for the generation of anti-F or anti-G antibodies for use in immunoassays, including enzyme-linked immunosorbent assays (ELISA), RIAs and other non-enzyme linked antibody binding assays or procedures known in the art. In ELISA assays, the  
20       vector first is administered to a host to generate antibodies specific to the RSV F or G protein or other paramyxovirus protein. These RSV F- or G-specific antibodies are immobilized onto a selected surface, for example, a surface capable of binding the antibodies,  
25       such as the wells of a polystyrene microtiter plate. After washing to remove incompletely adsorbed antibodies, a nonspecific protein such as a solution of bovine serum albumin (BSA) that is known to be antigenically neutral with regard to the test sample may  
30       be bound to the selected surface. This allows for blocking of nonspecific adsorption sites on the

immobilizing surface and thus reduces the background caused by nonspecific bindings of antisera onto the surface.

The immobilizing surface is then contacted with a sample, such as clinical or biological materials, to be tested in a manner conducive to immune complex (antigen/antibody) formation. This procedure may include diluting the sample with diluents, such as solutions of BSA, bovine gamma globulin (BGG) and/or phosphate buffered saline (PBS)/Tween. The sample is then allowed to incubate for from about 2 to 4 hours, at temperatures such as of the order of about 20° to 37°C. Following incubation, the sample-contacted surface is washed to remove non-immunocomplexed material. The washing procedure may include washing with a solution, such as PBS/Tween or a borate buffer. Following formation of specific immunocomplexes between the test sample and the bound RSV F specific antibodies, and subsequent washing, the occurrence, and even amount, of immunocomplex formation may be determined.

#### Biological Deposits

Certain vectors that contain the gene encoding RSV F protein and referred to herein have been deposited with the American Type Culture Collection (ATCC) located at 10801 University Boulevard, Manassas, VA 20110-2209, U.S.A., pursuant to the Budapest Treaty and prior to the filing of this application.

Samples of the deposited plasmids will become available to the public upon grant of a patent based upon this United States patent application and all restrictions on access to the deposits will be removed



at that time. Non-viable deposits will be replaced. The invention described and claimed herein is not to be limited in scope by plasmids deposited, since the deposited embodiment is intended only as an illustration of the invention. Any equivalent or similar plasmids that encode similar or equivalent antigens as described in this application are within the scope of this invention.

#### Deposit Summary

<u>Plasmid</u>	<u>ATCC Designation</u>	<u>Date Deposited</u>
pMP37	97905	Feb. 27, 1997
pMP42		

#### EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry and immunology used but not explicitly described in this disclosure and these Examples are amply reported in the scientific literature and are well within the ability of those skilled in the art.

**EXAMPLE 1**

This Example describes a scheme for construction of a Semliki Forest Virus (SFV) DNA expression vector containing a truncated RSV F gene as outlined in  
 5 Figures 1A to 1B.

Plasmid VR1012 was restricted with PstI and then made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid  
 10 pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAGATTTTGTTCAGCT  
 CCTGCCACCTCCGCTACGCGAGAGATTAACCAACCCACGATGGCCGCCAAAGT  
 15 GCATGTTGATATTGAGGCTGACAGCCCATTTCATCAAGTCTTGCAGAAGGCA  
 TTTCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA  
 ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA  
 CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from  
 pSFV1 with primers SAL-SFV having the nucleotide  
 20 sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:  
 5) and ECO-SFV having the nucleotide sequence 5'-  
 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The  
 resulting plasmid pMP38 was then restricted with EcoRV  
 and BamHI and then dephosphorylated. Plasmid pSFV1  
 25 link (see copending application no. \_\_\_\_\_ (b/o  
 1038-766)) was then restricted with SpeI and ligated to  
 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and  
 3). The ligation reaction was then restricted with  
 EcoRV to release most of the SFV-RSVF plus ribozyme  
 30 fragment. This fragment was then ligated to  
 EcoRV/BamHI restricted pMP38 to produce pMP41.

Example 2

This Example describes an alternative scheme for constructing plasmid pMp44 as outlined in Figure 2.

Plasmid VR1012 was restricted with PstI and then  
5 made blunt-ended with T4 DNA polymerase. The  $\beta$ -globin Intron II was excised out of vector pSG5 (Stratagene) and ligated into plasmid VR1012 to generate plasmid pIIE. Plasmid pIIE was then restricted with SalI and EcoRV and ligated to a PCR fragment having the  
10 nucleotide sequence:

TCGACATGGCGGATGTGTGACATACACGACGCCAAAAGATTTTGTTCAGCT  
CCTGCCACCTCCGCTACGCGAGAGATTAACCACCCACGATGGCCGCCAAAGT  
GCATGTTGATATTGAGGCTGACAGCCCATTCATCAAGTCTTTGCAGAAGGCA  
TTTCCGTCGTTTCGAGGTGGAGTCATTGCAGGTCACACCAAATGACCATGCAA  
15 ATGCCAGAGCATTTTCGCACCTGGCTACCAAATTGATCGAGCAGGAGACTGA  
CAAAGACACACTCATCTTGGAT (SEQ ID no: 7) generated from  
pSFVI with primers SAL-SFV having the nucleotide  
sequence 5'-TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no:  
5) and ECO-SFV having the nucleotide sequence 5'-  
20 TCCACCTCCAAGATATCCAAGATGAGTGTG (SEQ ID no: 6). The  
resulting plasmid pMP38 was then restricted with EcoRV  
and BamHI and then dephosphorylated. Plasmid pSFV1  
link (see copending application no. \_\_\_\_\_ (b/o  
1038-766)) was then restricted with SpeI and ligated to  
25 the hepatitis delta ribozyme (Fig. 5, SEQ ID nos: 2 and  
3).

The ligation reaction product was then restricted  
with EcoRV to release the SFV replicon plus the  
ribozyme having the nucleotide sequence as outlines in  
30 Figures 6A to 6C. This fragment was then ligated to  
the EcoRV/BamHI restricted pMP38 to produce pMP42. The

25

RSV F gene fragment was released from pMP37 by restriction with BamHI, and this fragment was ligated into the BamHI site of pMP42 to produce pMP44. The nucleotide sequence of pMP44 is shown in Figures 3A to

5 3E.

### EXAMPLE 3

This Example describes the immunization of mice with pMP44 and the immunogenicity results obtained.

BALB/C mice were immunized with plasmid pMP44 by the intramuscular (i.m.) route. The anterior tibialis muscles of six BALB/C mice were bilaterally injected with 2 x 100 µg of plasmid pMP44. This amount is equivalent to approximately 94µg of a conventional vector, based on copy number. These mice were boosted in an identical manner 4 weeks later. The control group was immunized with 2 x 25 µg of SFV-RSV F RNA as described in my aforementioned United States Application No. 08/923,558, except that the muscles were not pre-treated with cardiotoxin. The immunization protocol is set forth in the following Table I:

Table 1 Immunization protocol

Group	Prime	Route of Inoculation	Boost	Route of Inoculation
25	1 SFV-RSVF RNA <sup>1</sup>	Intramuscular	SFV-RSVF RNA <sup>1</sup>	Intramuscular
	2 pMP44 DNA <sup>2</sup>	Intramuscular	pMP44DNA <sup>2</sup>	Intramuscular

Mice were inoculated with:

1. 25µg of RNA was injected into each hind leg muscle in 50 µL of PBS
- 30 2. 100 µg of DNA was injected into each hind leg muscle in 50µL of PBS

Sera was obtained from the mice at 4 and 6 weeks. Anti-RSV F antibody titres (IgG) in these sera were determined by enzyme-linked immunosorbent assay (ELISA), as described in Example 3.

5 The anti-RSV F IgG antibody response in the sera of the BALB/C mice are summarized in Figure 4. The mice immunized with the DNA construct, pMP44, had higher anti-F titres than the mice immunized with the SFV-RSV F RNA.

10 Two weeks after the second immunization, mice were challenged intranasally with  $10^6$  plaque forming units (pfu) of the A1 strain of RSV (BG-4A). Animals were sacrificed 4 days later. Lungs were aseptically removed, weighed, and homogenized in 2 mL of complete  
15 culture medium. The virus titre in lung homogenates was determined in duplicate using vero cells, as previously described (ref. 41).

As seen in Table 2 below, immunization of mice with pMP44 DNA protected mice (5/6) against live RSV  
20 challenge, in contrast to the lack of protection when immunization with SFV-RSV F RNA was effected. This result contrasts with the complete protection which is obtained using SFV-RSV F RNA as described in U.S. Patent Application Nos. 08/923,558, 08/476,397 and  
25 08/896,500 where the results show protection after pretreatment with cardiotoxin.

Table 2

Group	Immunogen		Mean Virus Lung Titre	
	Prime	Boost	(log <sub>10</sub> /g±s.d)	% Protection
1	SFV-RSVF RNA	SFV-RSVF RNA	4.26	0
2	pMP44 DNA	pMP44DNA	2.12*	83

\* Limit of detection = 1.8

#### EXAMPLE 4

This Example describes the determination of anti-  
5 RSV F antibody titres.

Nunc-MaxiSorp plate wells were coated overnight at room temperature with 2.5 ng of immunoaffinity-purified RSV F protein diluted in 0.05M carbonate-bicarbonate buffer, pH 9.6. Wells were blocked for non-specific  
10 binding by adding 0.1% BSA in PBS for 30 min. at room temperature, followed by two washes in a washing buffer of 0.1% BSA in PBS + 0.1% Tween 20. Serial two or four-fold dilutions of mouse serum was added to the wells. After a one hour incubation at room  
15 temperature, plates were washed five times with washing buffer, and horseradish peroxidase (HRP) labeled conjugate was added at the appropriate optimal dilution in washing buffer. The total IgG assay used F(ab'), goat antimouse IgG (H+L specific)- HRP from Jackson  
20 Immuno Research Laboratory Inc. (Baltimore, MD, USA). Sheep anti-mouse IgG1-HRP from Serotec (Toronto, Ontario, Canada) was used in the IgG1 assay and goat anti-mouse IgG2a from Caltag Laboratories (San Francisco, CA, USA) was used in the IgG2a assay.  
25 Following one hour incubation at room temperature, the plates were washed five times with washing buffer, and hydrogen peroxide (substrate) in the presence of tetramethylbenzidine was added. The reaction was stopped by adding 2 M sulfuric acid. The colour was  
30 read in a Multiscan Titertek plate reader at an optical density (OD) of 450 nm. The titre was taken as the reciprocal of the last dilution at which the OD was

approximately double. This OD must be greater than the negative control of the assay at the starting dilution. The pre-immune serum of each animal was used as the negative control.

5

**SUMMARY OF THE DISCLOSURE**

In summary of this disclosure, the present invention provides certain novel alphavirus derived DNA vectors containing genes encoding RSV F or RSV G proteins, or other paramyxovirus proteins, methods of immunization using such vectors and methods of diagnosis using such vectors. Modifications are possible within the scope of this invention.

10

REFERENCES

1. McIntosh K. and Chanock R.M. in Fields B.N. and Knipe D.M. (eds). Virology. Raven Press, New York, 1990, pp.1045-1072.
2. Murphy B.R., Hall S.L., Kulkarni A.B., Crowe J.E., Collins P.L., Connors M., Karron R.A. and Chanock R.M., Virus Res 32, 13-36, 1994.
3. Osterweil D. and Norman D., Am Geriat Soc 36, 659-662, 1990.
4. Agius G., Dindinand G., Biggar R.J., Peyre R., Vaillant V., Ranger S., Poupet J.Y., Cisse M.F. and Casters M., J Med Virol 30, 117-127, 1990.
5. Katz S.L. in New vaccine development establishing priorities Vol 1. National Academic Press, Washington, 1985, pp. 3974 09.
6. Wertz G.W. and Sullender W.M., Biotechnology 20, 151-176, 1992 .
7. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M. and Meiklejohn G., Am J Epidemiol 89, 449-463, 1969.
8. Chin J., Magoffin R.L., Shearer I.A., Schieble J.H. and Lennette E.H., Am J Epidemiol 89, 449-463, 1969.
9. Belshe R.B., Van Voris L.P. and Mufson M.A., J Infect Dis 145, 311-319, 1982.
10. Kim R.M., Arrobio J.O., Pyles G., Brandt C.D., Camargo E., Chanock R.M. and Parrott R.H., Pediatrics 48, 745-755, 1971.
11. Gruber C. and Levine S., J Gen Virol 64, 825-832, 1983.
12. Olmstead R.A., Elango N. and Prince G.A., Proc Natl Acad Sci USA 83, 7462-7466, 1991.



13. Parrington M., Cockle S., Wyde P., Du R.-P., Snell E., Yan W.-Y., Wang Q., Gisonni L., Sanhueza S., Ewasysshyn M. and Klein M., *Virus Genes* 14, 65-74, 1997
- 5 14. Fulginiti, V.A., Eller, J.J., Sieber, O.F., Joyner, J.W., Minamitani, M. and Meiklejohn, G. (1969) *Am. J. Epidemiol.* 89 (4), 435-448.
- 10 15. Chin, J., Magoffin, R.L., Shearer, L.A., Schieble, J.H. and Lennette, E.H. (1969) *Am. J. Epidemiol.* 89 (4), 449-463.
- 15 16. Jensen, K.E., Peeler, B.E. and Dulworth, W.G. (1962) *J. Immunol.* 89, 216-226.
17. Murphy, B.R., Prince, G.A., Collins, P.L., Van Wyke-Coelingh, K., Olmsted, R.A., Spriggs, M.K., Parrott, R.H., Kim, H.-Y., Brandt, C.D. and Chanock, R.M. (1988) *Vir. Res.* 11, 1-15.
- 20 18. Hall, S.L., Sarris, C.M., Tierney, E.L., London, W.T., and Murphy, B.R. (1993) *J. Infect. Dis.* 167, 958-962.
- 25 19. Belshe, R.B., Karron, R.A., Newman, F.K., Anderson, E.L., Nugent, S.L., Steinhoff, M., Clements, M.L., Wilson, M.H., Hall, S.L., Tierney, E.L. and Murphy, B.R. (1992) *J. Clin. Microbiol.* 30 (8), 2064-2070.
- 30 20. Hall, S.L., Stokes, A., Tierney, E.L., London, W.T., Belshe, R.B., Newman, F.C. and Murphy, B.R. (1992) *Vir. Res.* 22, 173-184.
- 35 21. Van Wyke Coelingh, K.L., Winter, C.C., Tierney, E.L., London, W.T. and Murphy, B.R. (1988) *J. Infect. Dis.* 157 (4), 655-662.
- 40 22. Ray, R., Novak, M., Duncan, J.D., Matsuoka, Y. and Compans, R.W. (1993) *J. Infect. Dis.* 167, 752-755.
23. Ray, R., Brown, V.E. and Compans, R.W. (1985) *J. Infect. Dis.* 152 (6), 1219-1230.
- 45 24. Ray, R. and Compans, R.W. (1987) *J. Gen. Virol.* 68, 409-418.

25. Ray, R., Glaze, B.J., Moldoveanu, Z. and Compans, R.W. (1988) *J. Infect. Dis.* 157 (4), 648-654.
- 5 26. Ray, R., Matsuoka, Y., Burnett, T.L., Glaze, B.J. and Compans, R.W. (1990) *J. Infect. Dis.* 162, 746-749.
27. Ray, R., Glaze, B.J. and Compans, R.W. (1988) *J. Virol.* 62 (3), 783-787.
- 10 28. Ewasysshyn, M., Caplan, B., Bonneau A.-M., Scollard, N., Graham, S., Usman, S. and Klein, M. (1992) *Vaccine* 10 (6), 412-420.
- 15 29. Ambrose, M.W., Wyde, P.R., Ewasysshyn, M., Bonneau, A.-M., Caplan, B., Meyer, H.L. and Klein, M. (1991) *Vaccine* 9, 505-511.
- 20 30. Kasel, J.A., Frank, A.L., Keitel, W.H., Taber, L.H., Glezen W.P. *J. Virol.* 1984; 52:828-32.
31. Lehman, D.J., Roof, L.L., Brideau, R.J., Aeed, P.A., Thomsen, D.R., Elhammer, A.P., Wathen, M.W. and Homa, F.L. (1993) *J. Gen. Virol.* 74, 459-469.
- 25 32. Brideau, R.J., Oien, N.L., Lehman, D.J., Homa, F.L. and Wathen, M.W. (1993) *J. Gen. Virol.* 74, 471-477.
- 30 33. Ebata, S.N., Prevec, L., Graham, F.L. and Dimock, K. (1992) *Vir. Res.* 24, 21-33.
34. Hall, S.L., Murphy, B.R. and Van Wyke Coelingh, K.L. (1991) *Vaccine* 9, 659-667.
- 35 35. Strauss E.G. and Strauss J.H., in Schlesinger S.S. and Schlesinger M.i. (eds). *The Togaviridae and Flaviviridae*. Plenum Press, New York, 1986, pp.35-90.
- 40 36. Chapman, B.S.; Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., *Nucl. Acids. Res.* 1991, 19: 3979-3986.
- 45 37. Breathnack, R. and Harris, B.A., *Nucl. Acids Res.* 1983, 11: 7119-7136

38. Nabel, G.J. 1993, Proc. Natl. Acad. Sci. USA 90:  
11307-11311.
- 5 39. Tang et al., Nature 1992, 356: 152-154
40. Furth et al. Analytical Biochemistry, 1992, 205:  
365-368
- 10 41. Prince, G.A. et al, Am. J. Pathol. 93, 771 to 790,  
1978.

CLAIMS

What we claim is:

1. A vector, comprising:
  - 5 a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions to permit *in vivo* replication; and
  - a second DNA sequence encoding a paramyxovirus
- 10 protein or a protein fragment that generates antibodies that specifically react with the paramyxovirus protein, the second DNA sequence being inserted into a region of the first DNA sequence which is non-essential for replication, the first and second DNA sequences being
- 15 under transcriptional control of a promoter.
2. The vector of claim 1 wherein the paramyxovirus protein is selected from the group consisting of a parainfluenza virus (PIV) and a respiratory syncytial
- 20 virus (RSV).
3. The vector of claim 2 wherein the PIV protein is selected from the group consisting of PIV-1, PIV-2, PIV-3 and PIV-4
- 25
4. The vector of claim 3 wherein said PIV protein is selected from the group consisting of the HN and F glycoproteins of PIV-3.

5. The vector of claim 4 wherein the RSV protein is selected from the group consisting of the F or G glycoprotein of RSV.
- 5 6. The vector of claim 1 wherein the second DNA sequence encodes a full length RSV F or RSV G proteins.
7. The vector of claim 1, wherein the second nucleotide sequence encodes a truncated RSV F or RSV G  
10 protein lacking the transmembrane anchor and cytoplasmic tail.
8. The vector of claim 1 wherein the alphavirus is a Semliki Forest virus.
- 15 9. The vector of claim 1 wherein the first DNA sequence is the Semliki Forest viral sequence contained in plasmid pSFVI.
- 20 10. The vector of claim 1 wherein the promoter sequence is an immediate early cytomegalovirus (CMV) promoter.
11. The vector of claim 1 further comprising a third DNA sequence located adjacent the second DNA sequence  
25 to enhance the immunoprotective ability of the paramyxovirus protein when expressed in vivo from the vector in a host.
12. The vector of claim 11 wherein the third nucleotide  
30 sequence comprises a pair of splice sites to prevent aberrant mRNA splicing, in vivo whereby substantially

35

all- transcribed mRNA from the vector region  
administration encodes the RSV protein.

13. The vector of claim 12 wherein the third nucleotide  
5 sequence is located between the first nucleotide  
sequence and the promoter sequence.

14. The vector of claim 13 wherein said third  
nucleotide sequence is that of rabbit  $\beta$ -globin intron  
10 II.

15. The vector of claim 10 wherein said promoter  
sequence is an immediate early cytomegalovirus (CMV)  
promoter and the human cytomegalovirus Intron A  
15 sequence is provided downstream of the promoter and  
upstream of the third nucleotide sequence.

16. The vector of claim 15 further comprising a fourth  
nucleotide sequence at the 3'-end of the first  
20 nucleotide sequence to to ensure proper *in vivo* cleavage  
at the 3'-end of the first nucleotide sequence.

17. The vector of claim 16 wherein said fourth  
nucleotide sequence is a hepatitis delta virus ribozyme  
25 sequence.

18. The vector of claim 1 which has the identifying  
characteristics of plasmid pMP44 shown in Figure 2D.

30 19. The vector of claim 1 which has SEQ ID No: 1.

20. A method of immunizing a host against disease caused by infection with paramyxovirus, which comprises administering to the host an effective amount of a vector as claimed in claim 1.

5

21. The method of claim 21 wherein said vector has the identifying characteristics of plasmid pMP44 shown in Figure 2D.

10 22. The method of claim 21 wherein said vector has SEQ ID no: 1.

23. A method of using a gene encoding an RSV F or G protein or a fragment of an RSV or G protein capable of  
15 generating antibodies which specifically react with RSV F or G protein to protect a host against disease caused by infection with respiratory syncytial virus, which comprises:

isolating said gene;

20 operatively linking said gene to a DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus RNA genome replication regions in a region of said DNA sequence which is non-essential for replication  
25 to form a vector wherein said gene and DNA sequence are under transcriptional control of a promoter; and  
introducing the vector into the host.

24. The method of claim 23 wherein said gene encoding  
30 an RSV F protein encodes an RSV F protein lacking the transmembrane region.

25. The method of claim 24 wherein said promoter comprises the immediate early cytomegalovirus promoter.

- 5 26. The method of claim 25 including the step of:  
operatively linking said gene to an immunoprotective enhancing sequence to produce an enhanced immunoprotection to said RSV F protein in said host.

10

27. The method of claim 26 wherein said immunoprotective enhancing sequence is introduced into said vector between said control sequence and said gene.

- 15 28. The method of claim 27 wherein said immunoprotection enhancing sequence comprises a pair of splice sites to prevent aberrant mRNA splicing whereby substantially intact transcribed mRNA encodes an RSV F protein.

20

29. The method of claim 28 wherein said immunoprotection enhancing sequence is that of rabbit  $\beta$ -globin intron II.

- 25 30. The method of claim 23 wherein said vector is plasmid pMP44.

31. The vector of claim 23 wherein said vector has SEQ ID no: 1.

30



32. A method of producing a vaccine for protection of a host against disease caused by infection with respiratory syncytial virus (RSV), which comprises:

isolating a first DNA sequence encoding an RSV or G protein, from which the transmembrane anchor and cytoplasmic tail may be absent;

operatively linking said first DNA sequence to a second DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complete alphavirus genome replication regions in a region of said second DNA sequence which is non-essential for replication to form a vector wherein said first and second DNA sequences are under transcriptional control of a promoter; and

formulating the vector as a vaccine for in vivo administration.

33. The composition of claim 32 wherein said vector has the identifying characteristics of pMP44 shown in Figure 2D.

34. The method of claim 32 wherein said vector has SEQ ID no: 1.

35. A vaccine for administration to a host, including a human host, produced by the method of claim 32.

36. An immunogenic composition comprising an immunoeffective amount of a vector of claim 1.

37. The composition of claim 36 wherein said vector has the identifying characteristic of pMP44 in Figure 2D.

38. The composition of claim 36 wherein said vector has

5 SEQ ID no: 1.

1/16

Figure 1 Construction of pMP44




Fig. 1a

2/16





Fig 1B

3/16



+ Bam HI fragment  
from pM137



L. A. 12



Fig 1c




FIG 10

5/16


**Figure 1 Construction of pMP44**

fig. 1A

6/16




Fig. 20



Figure 2 Nucleotide sequence of plasmid pMP44

```

tcgcgcgttt  cggatgatgac  ggtgaaaacc  tctgacacat  gcagctcccg  gagacgggtca  60
cagcttctct  gtaagcggat  gccgggagca  gacaagcccc  tcagggcgcg  tcagcgggtg  120
ttggcggttg  tcggggctgg  cttactatg  cggtcatcaga  gcagattgta  ctgagagtg  180
accatagcgc  gttgaaata  ccgcacagat  gcgtaaaggag  aaaataccgc  atcagattgg  240
ctattggcca  ttgcatacgt  tgtatccata  tctaatatg  tacatttata  ttggctcatg  300
tccaacatta  ccggcatggt  gacattgatt  attgactagt  tattaatagt  aatcaattac  360
ggggtcatta  gttcatagcc  catatatgga  gttccgcgtt  acataactta  cgttaaatgg  420
cccgcctggc  tgaccgccca  acgacccccc  cccattgacg  tcaataatga  cgtatgttcc  480
catagtaacg  ccaataggga  ctttccattg  acgtcaatgg  gttggagtatt  tacggttaaac  540
tgcccacttg  gcagtacatc  aagtgtatca  tatgccaagt  acgcccccta  ttgacgtcaa  600
tgacggtaaa  ttggcccgcc  ggcattatgc  ccagtacatg  accttatggg  cctttctcac  660
ttggcagtc  atctacgtat  tagtcatcgc  tattaccatg  gtgatgcggg  ttggcagta  720
ctacaatggg  cgtggatagc  ggtttgactc  acgggggatt  ccaagtctcc  accccattga  780
cgtaaatggg  agtttgtttt  ggcacaaaa  tcaacgggac  ttccaaaaat  gtcgttaaca  840
ctccgcccca  ttgacgcaaa  tgggcggtag  gcgtgtacgg  tgggaggtct  atataagcag  900
agctcgttta  gtgaaccgtc  agatcgccgt  gagacgccat  ccaagctgtt  ttgacctcaa  960
tagaagacac  cgggacccat  ccagcctccg  cggccgggaa  cggctgattg  gaacgcggat  1020
tcccctggcc  aagagtgcgc  taagtaccgc  ctatagactc  tataggcaca  cccctttggc  1080
tcttatgcac  gctatactgt  ttttggcttg  gggcctatac  acccccgctt  ccttatgcta  1140
taggtgatgg  tatagcttag  cctataggtg  tgggttatgg  accattatg  accactcccc  1200
tattgtgac  gatcctttcc  attactaatc  cataacatgg  ctttttgcca  caactatctc  1260
tattgctat  atgccaatac  tctgtccttc  agagactgac  acggactctg  tatttttaca  1320
ggatgggttc  ccattttata  tttaaaaatt  cacatataca  acaacgcctg  tcccctggcc  1380
cgactctttt  attaaacata  gcgtggggtc  tccacgcgaa  tctcgggtac  gtgttccgga  1440
catgggtctc  tctccggtag  cggcggagct  tccacatccg  agccctggtc  ccatgctctc  1500
agcggctcat  ggtcgcctcg  cagctccttg  ctctaacacg  tggaggccag  acttagggac  1560
agcaaatgac  ccaccaccac  cagtggtccg  cacaagcccg  tggcggtagg  gtatgtgtct  1620
gaaaatgagc  gtggagattg  ggctcgacgc  gctgacgcag  atggaagact  taaggcagcg  1680
gcagaagaag  atgcaggcag  ctgagttggt  gtattctgat  aagagtacga  ggtaactccc  1740
gttgcggttc  tgttaacggg  ggagggcagt  gtactctgag  cagtactcgt  tgcgtcccg  1800
cgccgcccca  gacataatag  ctgacagact  aacagactgt  tcttttccat  gggctctttc  1860
cgatcctgag  aacttcaggg  tgagtttggg  gacccttgat  tgttctttct  ttctgctatc  1920
tgtaaaattc  atgttatatg  gagggggcaa  agttttcagg  gtgtgtttta  gaatggggaag  1980
atgtcccttg  tatccaccatg  gaccctcatg  ataattttgt  ttctttcact  ttctactctg  2040
ttgacaacca  ttgtctcttc  ttattttctt  ttcttttctt  gtaacttttt  cgttaaaactt  2100
tagcttgcat  ttgttaacgaa  tttttaaat  cacttttgtt  tatttgcag  attgtaagta  2160
ctttctctaa  tcaacttttt  ttcaaggcaa  tcagggtata  ttatttgta  ctccagcaca  2220
gttttagaga  acaattgtta  taattaaatg  ataaggtaga  atatttctgc  atataaattc  2280
tggtcgtgct  ggaatatatt  ttattggtag  aaacaactac  atctgtgtca  tcatcctgcc  2340
tttctcttta  tggttacaat  gatatacact  gtttgagatg  aggataaaaat  actctgagtc  2400
caaaccgggc  cctctctgta  accatgttca  tgccttcttc  ttttctctac  agctcctggg  2460
caacgtgctg  gttattgtgc  tgtctcatca  ttttggcaaa  gaattgtaat  acgactcact  2520
atagggcgaa  ttgtcacctg  cgtcgacatg  gcggatgtgt  gacatacagc  acgccaagaag  2580
attttgttcc  agctcctgcc  acctccgcta  cgcgagagat  taaccacca  cgatggccgc  2640
caaagtgcac  gttgatattg  aggtgcacag  cccattcatc  aagtctttgc  agaaggcatt  2700
tccgtcgttc  gaggtggagt  cattgcaggt  cacaccaaat  gaccatgcaa  atgccaagagc  2760
attttgcac  ctggctacca  aattgatcga  gcaggagact  gacaaagaca  caactcatct  2820
ggatctcgcc  agtcgccttc  ccaggagaa  gatgtctacg  cacaaatacc  actgcgtatg  2880
ccctatcgcc  agcgcagaa  accccgaaa  gctcgatagc  tacgcacaaga  aactggccagc  2940
ggcctccggg  aaggtgctgg  atagagagat  cgcaggaaaa  atcaccgacc  tgcagaccgt  3000
catggctacg  ccagacgctg  aatctctac  cttttgcctg  catcacagag  tcaactgtgc  3060
tacggcagcc  gaagtgccg  tataccagga  cgtgtatgct  gtacatgcac  caactcgtct  3120
gtaccatcag  gcgatgaaag  gtgtcagaac  ggcgtattgg  attgggtttg  acacccccc  3180
gtttatgttt  gacgcgctag  caggcgcgta  tccaacctac  gccacaaact  gggccgacga  3240

```

```

gcagggtgtta caggccaggga acataggact gtgtgcagca tccttgactg agggaaagact 3300
cgccaaactcg tccattctccc gcaagaagca attgaaacct tgcgacacag tcatgttcttc 3360
ggttagactct acattgtata ctgagagcag aaagctactg aggagctggc acttacccttc 3420
cgtattccac ctgaaaggta aacaatcctt tacctgtagg tgcgatacca tctgtatcatg 3480
tgaagggtac gtagttaaga aaatcactat gtgccccggc ctgtacggta aaacggtagg 3540
gtacgccgtg acgtatcacg cggagggtatt cctagtgtgc aagaccacag acactgtcaa 3600
aggagaanga gtctcattcc ctgtatgcac ctacgtcccc tcaaccatct gtgtacaaat 3660
gactggcata ctacgcaccg acgtcacacc ggaggacgca cagaagtgtg tagtgggtatt 3720
gaatcagagg atagtgtgta acggaagaac acagcgaac actaacacga tgaagaacta 3780
tctgtctccg attgtggccg tcgcatttag caagtgggag agggaaatac aggcagacct 3840
tgatgatgaa aaacctctgg gtgtccgaga gaggtcactt acttgctgct gcttgtgggc 3900
atttaaaagc aggaagatgc acaccatgta caagaaacca gacacccaga caatagtga 3960
ggtgccttca gagtttaact cgttcgtcat cccgagccta tgggtctacg gcctcgcaat 4020
cccagtcaga tcacgcatta agatgctttt ggccaagaag accaaggcag agttaatacc 4080
tgttctcgac gcgtcgtcag ccagggtatg tgaacaagag gagaaggaga ggttgaggc 4140
cgagatgact agagaagcct taccacccct cgtccccact gcgcggcgag agacgggact 4200
ctctgacatc gcagttyaag aactagagta tcacgcaggt gcagggtgtc tggaaacacc 4260
tcgcagcgcg ttgaaagtca ccgcacagcc gaacgcagta ctactaggaa attactagt 4320
tctgtccccg cagaccgtgc tcaagagctc caagtgtgcc cccgtgcacc ctctagcaga 4380
gcaggtgaaa ataatacac ataacgggag ggccggcggt taccaggtgc acggtatga 4440
cgccagggtc ctactaccat gtggatcgcc catcccgctc cctgagttt aagcctttag 4500
cgagagtcac actatggtgt acaacgaaa ggagttcgtc aacaggaaac tataccatat 4560
tgccgttcac ggacgtcgc tgaacaccga cagggagaac tacgagaaga tcagagctga 4620
aagaactgac gccagtagc tgttcgact agataaaaa tgctgcctga agagagagga 4680
agcgtcgggt ttggtgttg tgggagagct aaccaacccc ccgttccatg aattcgcta 4740
cgaaggcggt aagatcagcc cgtcggcacc atataagact acagttagtag gactctttgg 4800
ggttccggga tcaggcaagt ctgctattat taagagcctc gtgaccaaac acgatctgtg 4860
caccagcgcc aagaaggaga actgccagga aatagttaac gacgtgaaga agcacccggy 4920
gaaggggaga agtagggaaa acagtgaact catcctgcta aacgggtgtc gctgtccgt 4980
ggacatccta tatgtggagc aggtctttgc ttgccattcc ggtactctgc ttgccctaat 5040
tgctcttgtt aaacctcgga gcaaatggtt gttatcgga gaccccaagc aatgcggatt 5100
cttcaatatg atcgacttta aggtgaact caaccacaac atctgactg atctgacta 5160
taaaagtata tccagcgtt gccacgcgtc agtcacggcc atcgtgtcta cgttgacta 5220
cgaggcgcaag atgcgcagga ccaacccgtg caacaaaccc ataactcatg acccacagg 5280
acagaccaag ccaagccag gagacatcgt gtaaacatgc ttccgaggct gggcaagca 5340
gctgcagttg gactaccgtg gacacgaagt catgacagca gcagcatctc agggcctcac 5400
ccgcaaaagg gtatacgccc taaggcagaa ggtgaatgaa aatcccttgt atgccctgc 5460
gtcggagcac gtgaatgtac tgcgtgacgc cactgaggat aggtcgtgtg ggaaacgcgt 5520
ggccggcgat ccctggatta aggtcctatc aaacattcca cagggttaact ttacggccac 5580
attggaagaa tggcaagaag aacacgacaa aataatgaag gtgattgaag gaccggctgc 5640
cgtgtggac gcgttccaga acaaaagcga cgtgtgttg gcgaaaagcc ttggtcctgt 5700
cctggacact gccggaatca gattgacagc agaggagtgg agcaccataa ttacagcatt 5760
taaggaggac agagcttact ctccagtgtt ggccttgaat gaaatttgca ccaagtacta 5820
tggagttgac ctggacagt gcctgttttc tgcccgaag gtgtccctgt attacgagaa 5880
caaccactgg gataacagac ctgtgtggaag gatgtatgga ttcaatgccg caacagctgc 5940
caggctggaa cctagacata ccttcctgaa ggggcagtgg catacgggca agcaggcagt 6000
tatcgagaa agaaaaatcc aaccgcttcc tgtgctggac aatgtaattc ctatcaaccg 6060
caggctgcgc caccgctcgt tggctgagta caagacggtt aaaggcagta ggggtgagtg 6120
gctggtcaat aaagttaagag ggtaccacgt cctgctggtg agtgagtaca acctgctctc 6180
gcctcgagcg aggtcactt ggttgcacc gctgaatgtc acaggcgccg ataggtgcta 6240
gcacttaagt ttaggactgc cggctgacgc cggcaggttc gacttggctt ttgtgaacat 6300
tcacacggaa ttcagaatcc accactacca gcagtgtgtc gaccacgcca tgaagtgca 6360
gatgcttggg ggagatgcgc tacgactgct aaaacccggc ggcattctga tgagagctta 6420
cggataccgc gataaaatca gcgaagccgt tgtttctccc ttaagcagaa agttctcgtc 6480
tgcaagagtg ttgcgcccg atgtgtcac cagcaatata gaagtgtct tgctgttctc 6540
caactttgac aacggaaga gaccctctac gctacaccag atgaatcca agctgagtc 6600
cgtgtatgcc ggagaagcca tgcacacgac cgggtgtgca ccatctaca gagttaagag 6660

```

agcagacata gccacgtgca cagaagcggc tgtggttaac gcagctaabc cccgtggaac 8720  
 tgtaggggat ggcgtatgca gggccgtggc gaagaaatgg ccgtcagcct ttaaggagagc 6780  
 agcaaacacca gtgggcacaa ttaaaacagc catgtgcggc tcgtaccocg tcattccacgc 6840  
 tgtagcgctg aattctctgt ccacgactga agcggaaagg gaccgcgaat tggccgctgt 6900  
 ctaccgggca gtggcggccg aagtaaacag actgtcactg agcagcgtag ccatcccgct 6960  
 gctgtccaca ggaagtgtca gcggcggaag agataggctg cagcaatccc tcaaccatct 7020  
 attcacagca atggacgcca cggacgctga cgtgaccatc tactcgagag acaaaagtgt 7080  
 ggagaagaaa atccaggaa gccattgacat gaggacggct gtggagtgc tcaatgatga 7140  
 cgtggagctg accacagact tgggtgagagt gcacccggag agcagcctgg tgggtcgtaa 7200  
 gggctacagt accactgacg ggtcgtctga ctctactttt gaaggtacga aattcaacga 7260  
 ggctgctatt gatattggcag agatactgac gttgtggccc agactgcaag aggcacaacya 7320  
 acagatatgc ctatacggcg tgggcgaaac aatggacaac atcagatcca aatgtccggt 7380  
 gaaagattcc gattcatcaa cactcccag gacagtcccc tgccgtgccc gctacgcaat 7440  
 cagagagaaa cggatogccc gccttaggtc acaccaagtt aaaagcatgg tgggttgcctc 7500  
 atcttttccc ctcccgaat accattgtaga tggggtgcag aaggtaaaag gcgagaaggt 7560  
 tctctgttgc gaccgcagg taccttcagt ggttagtccg cggaaagtat ccgcatctac 7620  
 gacggaccac tcagatcgggt cgttacgagg gtttagcttg gactggacca ccgactcgtc 7680  
 ttccactgcc agcgatacca tgtcgttacc cagtttgca tegtgtgaca tcgactcgat 7740  
 ctacagacca atggctccca tagtagtgac ggttgacgta caccctgaac ccgcaggcat 7800  
 cggcgacctg cggcgagatg tgcacccgta acccgagac catgtggacc tcgagaaccc 7860  
 gattctccca ccgcccgcga agagagctgc atacctgccc tcccgcggcg cggagcgacc 7920  
 ggtgccggcg ccgagaaagg ccagcctgac cccaaggact gcgtttagga acaagctgcc 7980  
 tttgagcttg ggcgactttg acgagcacga ggtcgatgcy ttggccctcg ggtattacttt 8040  
 cggagacttc gacgacgtcc tgcgactagg ccgcccgggt gcatatatt tctcctcgga 8100  
 cactggcagc ggcattttac aacaaaaatc cgttaggcag cacaatctcc agtgcgcaca 8160  
 actggatgcy gtcacaggag agaaaaatga cccgccaaaa ttggaactcy agagggagaa 8220  
 gctgttgctg ctgaaaaatg agatgcaccc atcggaggct aataagagtc gatccagtc 8280  
 tcgcaaaagt gagaactga aagccacggt ggtggacagg ctccatctgg gggccagatt 8340  
 gtacacggga cggcagctag gccgcatacc aacatacgcy gttcggatcc cccgcocctg 8400  
 gtaactccct accgtgatcg aaagattctc aagcccogat gtagcaatcg cagcgtgcaa 8460  
 cgaataccta tcagaaaatt acccaacagt ggcgtcgtac cagataacag atgaatacga 8520  
 cgcatacttg gacatggttg acgggtcgga tagttgcttg gacagagcga cattctgcgc 8580  
 ggcgaagctc cgtgtctacc cgaacactca tgcgtaccac cagccgactg ccagcagtgc 8640  
 cgtcccgtca ccttttcaga acacactaca gaaogtgcga gcggccgcca ccaagagaaa 8700  
 ctgcaacgtc ccgcaaatgc gagaactacc caccatggac tcggcagtg tcaactgga 8760  
 gtgttcaag cgtatgcct gctccggaga atattgggaa gaatatgcta aacaacctat 8820  
 ccggataacc actgagaaca tcaactaccta tgtgaccaa ttgaaagggc cgaagctgc 8880  
 tgccctgttc gctaagacccc acaacttgggt tccgctgca gagggttccca tggacagatt 8940  
 caccgtcgac atgaaacgag atgtcaaatg cactccaggg acgaaacaca cagaggaag 9000  
 acccaagtc caggyaatcc aagcagcgga gccattggcg accgcttacc tgtcgcgcat 9060  
 ccacagggaa ttgatgaagg gactaaatgc tgtgttaacy cctaactgco acacattgtt 9120  
 tgatatgtcg gccgaagact ttgacgcgat catcyccctc cacttccacc caggagaccc 9180  
 ggttctagag accgacattg catcattcga caaaagccag gacgactcct tggctcttac 9240  
 aggtttaatg atcctcgaa atctaggggt ggtacagtac ctgctggact tgatcgagcg 9300  
 agcctttggg gaaatatcca gctgtcacct accaactggc acgcgtctca agttcggagc 9360  
 tatgatgaaa tccggcatgt ttctgacttt gtttattaac actgttttga acatcaccat 9420  
 agcaagcagg gtactggagc agagactcac tgaactccgc tgtcgccgct tcatcgcgga 9480  
 cgacaacatc gttcacggag tgatctccga caagctgatg gcggagaggt gcgcgtcgtg 9540  
 ggtcaacatg gaggtaaga tcattgacgc tgcatagggc gaaaaacccc catatttttg 9600  
 tgggggattc atagtgtttg acagcgtcac acagaccgcc tgccgtgttt cagacccact 9660  
 taagcyccgt tccaagtgg gtaagccgct aacagctgaa gacaagcagg gacaagcagg 9720  
 gcgacgagca ctgagtgcag aggttagcaa gtggttccgg acaggcttgg gggccgaact 9780  
 ggaggtggca ctaacatcta ggtatgaggt agagggtgc aaaaagtatc tcatagccat 9840  
 ggccacattg gcgagggaca ttaaggcgtt taagaaattg agaggacctg ttatacacc 9900  
 ctacggcggt cctagattgg tgcgttaata cacagaattc tgattggatc atagcgcat 9960  
 attatggat cccgcggcgc gaattcgcca cgaatcaaa tggagtgtct atctctcaa 10020  
 gcaaatgcaa ttaccacaat cctcactgca gtcacatttt gttttgcttc tggctcaaac 10080

10/16

atcactgaag	aattttatca	atcaacatgc	agtgacagta	gcaaaaggcta	tcttagtgct	10140
ctgagaactg	gttggtatag	cagtggtata	actatagaat	taagttaat	caaggaaaaa	10200
aagtgtcaatg	gaacagatgc	taaggtaaaa	ttgataaaa	agaatcataga	tgaatataaa	10260
aatgctgttaa	cagaattgca	gttgctcatg	caaagcacac	cagcagcaaaa	caatcgagcc	10320
agaagaagac	taccaaggtt	tatgaattat	acactcaaca	atgccaaaaa	acccaagtga	10380
acattaagca	agaaaaggaa	aagaagattt	cttggttttt	tgttaggtgt	tggatctgca	10440
atcgccagtg	gcgttgctgt	atctaaaggtc	ctgcacctag	aaggggaagt	gaacaagatc	10500
aaaagtgtcc	tactatccac	aaacaaggct	gtagtcagct	tatcaaatgg	agtttagtgc	10560
ttaaccagca	aagtgttaga	cctcaaaaac	tatatagata	aacaattgtt	acctattgtg	10620
aacaagcaaaa	gctgcagcat	atcaaatata	gaaactgtga	tagagtcca	acaaaagaac	10680
aacagactac	tagagattac	caggggaattt	agtgttaatg	caggtgtaac	tacacctgta	10740
agcacttaca	tgttaactaa	tagtgaatta	ttgtcattaa	tcaatgatat	gcctataaca	10800
aatgatcaga	aaaagttaat	gtccacaat	gttcaaatag	ttagacagca	aagttactct	10860
atcatgtcca	taataaaaaga	ggaagtctta	gcattatgtag	tacaattacc	actatattgt	10920
gttatagata	cacctgtgtg	gaaactacac	acatcccctc	tatgtacacg	atccacaaaa	10980
gaaggggtcca	acatctgttt	aacaagaact	gacagaggat	ggtactgtga	caatgcagga	11040
tcagtatctt	tcttcccaca	agctgaaaca	tgtaaaagttc	aatcaaatcg	agttattttgt	11100
gacacaaatga	acagtttaac	attaccaagt	gaaataaatc	tctgcaatgt	tgacatatct	11160
aaaccccaaat	atgattgttaa	aattatgact	tcaaaaacag	atgtaagcag	ctccgttatc	11220
acatctctag	gagccattgt	gtcatgctat	ggcaaaacta	aatgtacagc	atccataaaa	11280
aatcggtgaa	tcataaagac	attttctaac	gggtgcgatt	atgtatcaaa	taaaaggtat	11340
gacactgtgt	ctgtaggttaa	cacattatat	tatgtaataa	agcaagaagg	taaaagctct	11400
tatgtaaaa	gtgaaccaat	aataaatttc	tatgacccat	tagtattccc	ctctgatgaa	11460
tttgatgcac	caatatctca	agtcacacgag	aagattaaac	agagcctagg	atattatcgt	11520
aaatccgatg	aattattaca	taatgtaaat	gctggtaaat	ccaccacaaa	tcttatcgct	11580
tgataatgag	gatccagatc	ccgggtaatt	aattgaatta	catccctacg	caaacgtttt	11640
acggcgcccg	gtggcgcccg	cgcccgcccg	cccgctcctg	gocgttgacg	gccactccgg	11700
tggtctccctg	cgctcccgac	ttccaggccc	agcagatgca	gcaactcacc	acggccgtaa	11760
atgcgctgac	aatgagacag	aacgcaattg	ctcctgctag	gcctcccaaa	ccaaagaaga	11820
agaagacaac	caaaccaaa	ccgaaaaacg	agcccaagaa	gatcaacgga	aaaacgcagc	11880
agcaaaagaa	gaaagacaag	caagccgaca	agaagaagaa	gaaacccgga	aaaagagaaa	11940
gaatgtgcat	gaagattgaa	aatgactgta	tcttcgtatg	cggttagcca	cagtaacgta	12000
gtgtttccag	acatgtcggg	caccgcacta	tcattgggtcg	agaaaaatctc	gggtgggtctg	12060
ggggccttcg	caatcggcgc	tatcctgggtg	ctgggtgtgg	tcacttgcat	tgggctccgc	12120
agataaagta	gggtaggcaa	tggcattgat	atagcaagaa	aattgaaaac	agaaaagaatt	12180
agggtaagca	atggcatata	accataactg	tataacttgt	aacaagacgc	acaagaacct	12240
gcgcgaattg	cccgtgtgtc	cgccctcacg	aaactcgggg	caactcatat	tgacacatta	12300
attggcaata	attgggaagct	tacataagct	taattcgacg	aataattgga	tttttatttt	12360
attttgcaaa	tggtttttaa	tatttccaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	12420
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	gcgggtcggc	atggcatctc	12480
cacctctctg	cggtccgacc	tgggcattccg	aaggaggacg	cacgtccaact	cggtatggcta	12540
agggagagat	ccagatctgc	tgtgcctctc	agttgcaccg	catctgttgt	tggccctccc	12600
cccgtgcctt	ccctgaccct	ggaaggtgcc	actcccactg	tcttttctta	ataaaatgag	12660
gaaattgcat	cgcattgtct	gagttagtgt	cattctattc	tggggggctg	ggtggggcag	12720
gcagacaaag	gggaggattg	ggaagacaat	agcaggcatg	ctgggggatgc	ggtgggctct	12780
atgggtaccc	aggtgctgaa	gaattgaccc	ggttctctct	gggcccagaaa	gaagcaggca	12840
catccccctc	tctgtgacac	accctgtcca	cgccctcggt	tcttagttcc	agccccactc	12900
ataggacact	catagctcat	gagggtccg	ccttcaatcc	caccgcgtta	agtagttgga	12960
gcggtctctc	cctccctcat	cagcccacca	aaccaaacct	agcctccaag	atgtggaaaga	13020
aattaaagca	agataggcta	ttaagtgcag	agggagagaa	aatgcctcca	acatgtgagg	13080
aaagtaatgag	agaaatcata	gaatttcttc	cgcttctctg	ctcactgcctc	ggctgcgctc	13140
ggtcgttcgg	ctgcggcgag	cggtatcagc	tcactcaaa	gcggtataac	gggtatccac	13200
agaatcagg	gataacgcag	gaagaacat	gtgagcaaaa	ggccagagaa	ggctagcgaa	13260
ccgtaaaaag	gcccgcgttc	tggcggtttt	ccataggctc	cgccccctg	acgagcatca	13320
caaaaaatga	cgctcaagtc	agaggtggcg	aaacccgaca	ggactataaa	gataccaggc	13380
gtttccctct	gggaagctccc	tcgtgcgctc	tctgttccg	acctgcgcgc	taccggata	13440
cctgtccgcc	tttctccctt	cgggaagcgt	ggcgctttct	catagctcac	gctgtaggta	13500

H43D

11/16

```

tctcagttcg gtgtaggctcg ttcgctccaa gctgggctgt gtgcacgaac ccccggttca 13560
gcccgacccgc tgcgccttat ccggttaacta tgcgtcttgag tccaacccgg taagacacga 13620
cttatcgcca ctggcagcag ccactggtaa caggattagc agagcagaggt atgtaggcgg 13680
tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg 13740
tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 13800
caaacaaacc accgctggta gcggtggttt tttgtttgc aagcagcaga ttacgcgcag 13860
aaaaaaagga tctcaagaag atcctttgat cttttctacg gggctcgacg ctcagtgga 13920
cgaaaactca cgttaaggga ttttggcat gagattatca aaaaggtatc tcacctagat 13980
ccttttaaat faaaaatgaa gttttaatc aatctaaagt atatatgagt aaacttgggt 14040
tgacagttac caatgcctaa tcagtgggc acctatctca gcgatctgtc tatttcgttc 14100
atccatagtt gcctgactcg gggggggggg gcgctgaggt ctgcctcgtg aagaaggtgt 14160
tgctgactca taccaggcct gaatcgcccc atcatccagc cagaagatga gggagccagc 14220
gttgatgaga gctttgttgt aggtggacca gttggtgatt ttgaactttt gctttgccac 14280
ggaaacggtct gcgttgtcgg gaagatcggt gatctgatcc ttcaactcag caaaagtctg 14340
atttattcaa caaagccgcc gtcccgctaa gtcagcgtaa tgctctgccca gtgttacaac 14400
caattcaacca attgtgatta gaaaaactca tcgagcatca aatgaaactg caatttattc 14460
atatcaggat tatcaatacc atatttttga aaaagccgtt tctgtaatga aggagaaaac 14520
tcaccgaggc agttccatag gatggcaaga tcttggtatc ggtctgcatc tccgactcgt 14580
ccaacatcaa tacaaactat taatttcccc tctgcaaaaa taaggttatc aagtgagaaa 14640
tcaccatgag tgacgactga atccggtgag aatggcaaaa gcttatgcat ttctttccag 14700
acttggtcaa caggccagcc attacgctcg tcatcaaaat cactcgcac caccaaaccc 14760
ttattcattc gtgattgcgc ctgagcgaga cgaatacgc gatcgctgtt aaaaggacaa 14820
ttacaacacg gaatcgaatg caaocggcgc aggaacactg ccagcgcatc aacaatattt 14880
tcacctgaat caggatattc ttctaatacc tggaaatgct ttttcccggg gatcgacgtg 14940
gtgagtaacc atgcacatc aggagtacgg ataaaatgct tgatggtcgg aagaggcata 15000
aattccgtca gccagtttag tctgaccatc tcatctgtaa catcatttgc aacgtaacct 15060
ttgccatggt tcagaacaaa ctctggcgca tggggcttcc catacaatcg atagattgtc 15120
gcacctgatt gcccgacatt atcgcgagcc catttatacc catataaatc agcatccattc 15180
ttggaattta atcgcgccct cgagcaagac gtttcccggt gaatatgggt cataacgttc 15240
cttgatttac tgtttatgta agcagacagt tttattgttc atgatgatat atttttatct 15300
tgtgcaatgt aacatcagag attttgagac acaacgtggc tttccccccc ccccatttat 15360
tgaagcattt atcagggtta ttgtctcatg agcgatata tatttgaatg tatttagaaa 15420
aataacaaa taggggttcc gcgcacattt ccccgaaaag tgccacctga cgtctaagaa 15480
accattatta tcatgacatt aacctataaa aataggcgta tcacgaggcc ctttcgtc 15538

```

12/16

Figure 4. Anti-RSV F titres in sera from mice taken 4 weeks after priming and 2 weeks after boosting




Figure 5 Ribozyme linker for pMP42

5' CTAGCGGTCGGCATGGCACTCCACCTCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGACGTCCTCGGATGGCTAAGGAGA 3'  
GCCCAGCCGTACCGTAGAGTTGAGAGCGCCAGGCTGGACCGTAGGCTTCCTCCTCGTGCAGGTGAGCCTACCGATTCCCTCTCTAG

Figure 6A5FV Eco RV-Spe I fragment ligated to ribozyme

	atcgccagtg	cgccttccag	gagaatgatg	tctacgcaca	aataccactg	cgtatgccc	60
	atcgccagtg	cagaagagccc	cgaaaggctc	gatagctacg	caagaagact	ggcagggccc	120
	gtcggaagtg	tgctggtag	agagatcgca	ggaaaaatca	ccgactcgca	gaccgtcatg	180
5	gctacgccag	acgctgaatc	tctacctttt	tgccctgcata	cagacgtcac	gtgctgtacg	240
	gcacggcgaag	tggccgtata	ccaggacgtg	tatgctgtac	atgcaccnac	atcgcgtgac	300
	catcaggcga	tgaagggtgt	cagaacggcg	tattggattg	ggcttgacac	caccccggtt	360
	atgtttgacg	cgctagcagg	cgctatccca	acctacggca	caaatctggg	cgacgagcag	420
	gtgttacagg	ccaggaaacat	aggactgtgt	gcagcatcct	tgactgaggg	aagactcggc	480
10	aaactgtcca	ttctccgcaa	gaagcaattg	aaactctgcy	acacagtcac	gttctcggtg	540
	ggatctacat	gtacactgga	gagcagaag	ctactgagga	gctggcactt	acccctccga	600
	ttccacactga	aaggtaaaaca	atcctttacc	tgtaggtgcy	ataccatcgt	atcatgtgaa	660
	gggtacgtatg	ttasgaaaat	cactatgtgc	cccgccctgt	acggtaaaac	ggtagggtag	720
	gcggtgacgt	atcacgcgga	gggattccca	gtgtgcaaga	ccacagacac	tgtcaaggga	780
15	gaaagagctc	cattccctgt	atgcacctac	gtccctccaa	ccatctgtga	tcaaatgact	840
	ggatatactg	cgaccgcagt	cacacgggag	gaocgcacaga	agttgttagt	gggattgaat	900
	cagaaggatag	ttgtgaacgg	aagaacacag	cgaaacacta	acaogatgaa	gaactatctg	960
	cttccgattg	tggccgtcgc	atttagcaag	tgggagggg	aatacaagg	agaccttgat	1020
	gatgaaaaac	ctctgggtgt	cagagagagg	tcacttactt	gctgtctgct	gtgggcatct	1080
20	aaaacgagga	agatgcacac	catgtacaag	aaaccagaca	cccagacac	agtagaggtg	1140
	ccctcagagt	ttactctggt	cgctcatccg	agcctatggt	ctacagggct	cgcactccca	1200
	gtcagatcac	gcattaaagt	gcttttggcc	aagaagacca	agcgagagtt	aatacctggt	1260
	ctcgacgcgt	cgtagccgag	ggatgctgaa	caagaggaga	aggagaggtt	ggagggccag	1320
	ctgactagag	aagccttacc	accctctgct	cccatcgccg	cgccggagac	gggagtgctc	1380
25	gaogtcgag	ttgaagaact	agagtatcac	gcaggtgcag	gggtcgtgga	aacacctcgc	1440
	agcgcttcta	aagtcacccg	acagccgaac	gacgtactac	taggaatata	cgtagtctct	1500
	tcaccccgaga	cggtgtccaa	gagctccaa	ttggccccc	tgcacccctc	agcagagcag	1560
	gtgaaaaata	taacacataa	cgggagggcc	ggcggttacc	aggtcgacgg	atatcgaggg	1620
	agggctccac	taccatgtgg	atcgcccat	ccggtccctg	agtttcaagc	ttgtagagcg	1680
30	agggccacata	tgggtacaaa	cgaaaggagg	ttcgtcaaca	ggaaactata	ccatattgcc	1740
	gttcacggcag	cgtcgttgaa	caccgacgag	gagaactacg	agaaagtccg	agctgaagga	1800
	actgacgcgc	agtagctggt	cgacgtagat	aaaaaatgct	gcgtcaagag	agagggaagc	1860
	tcgggtttgg	tggtgggtgg	agagctaaac	aaaccccggt	tccatgaatt	cgccatcgaa	1920
	gggctgaaga	tcaggccgct	ggcaccata	aagactacag	tagtaggagt	ctttgggggt	1980
35	ccgggatcag	gcaagtctgc	tattattaag	agcctcgtga	ccaaacacga	tctggctacc	2040
	agcggaaga	aggagaactg	ccaggaaata	gttaacgacg	tgaagaagca	cccggggaag	2100
	gggacaagta	gggaaaaacg	tgactccatc	ctgctaaacg	ggtgtcgtcg	tgccgtggag	2160
	atcctatatg	tggacgaggg	tttcgcttgc	cattccggta	ctctgctggc	cctaatttgt	2220
	cttgttaaac	ctcggagcaa	agtggtgtta	tgcggagacc	ccaagcaatg	cggaattcttc	2280
40	aatatgatgc	agcttaagg	gaacttcaac	cacaacatct	gcactgaagt	atgtcataaa	2340
	agtatatcca	gacgttgca	gcgtccagtc	acggccatcg	tgtctacgtt	gcactacgga	2400
	ggcaagatgc	gcacgaccaa	cccggtcaac	aaacccataa	tcatagacac	cacaggacag	2460
	accaagccca	agccagggga	catcgtgtta	acatgtctcc	gaggtctggc	aaagcagctg	2520
	cagttggact	accgtggaca	cgaagtcag	acagcagcag	catctcaggg	cctcacccgc	2580
45	aaaggggtat	acgcccgaag	gcagaagggt	aatgaaatc	ccttgtatgc	ccctggctgc	2640
	gagcagctga	atgtactctg	gacgcgcact	gaggtatggc	tgggttgaaa	aaagctggcc	2700
	gtggatccct	ggatcaagg	ccatcaaac	attccacagg	gttaactttac	ggccacattg	2760
	gaagaatggc	aagaagaaca	cgacaaaata	atgaaggtga	ttgaaggacc	gggtcgccct	2820
	gtggacgcgt	tcacgaacaa	agcgaaacgt	tgttggggga	aaagcctggg	gcctgtctcg	2880
50	gacactgcgc	gaatcagatt	gacagcagag	gagtgagaca	ccataattac	agtcatttaag	2940
	gaggacagag	cttactctcc	agtggtggcc	ttgaatgaaa	tttgacccaa	gtactattgga	3000
	gtgacactgg	acagtgccct	gttttctgcc	ccgaaggtgt	ccctgtatta	cgagaaacac	3060
	cactgggata	acagacctgg	tggaaaggatg	tatggattca	atgcgcacac	agctgccagg	3120
	ctggaagcta	gacataccct	cctgaagggg	cagtggcata	cggycaagca	ggcagttatc	3180
55	gcagaagaaa	aaatccaaac	gctttctgtg	ctggacaatg	taattccat	caaccgcag	3240
	ctgcgcgacg	ccctggtggc	tgagtacaag	acggttaaa	gcagttaggt	tgagtggtgt	3300
	gtcaataaag	taagagggtg	ccacgtcctg	ctggtgagtg	agtaacacct	gctttgctct	3360
	cgacgcaggg	tcacttggtt	gtcacccgctg	aatgtcacag	gcgcgcatag	gtgctacgac	3420



Ac.66

	ctaagtttag	gactgcccgc	tgacgcccgc	aggttcgact	tggctcttgt	gaacattcac	3480
	acggaattca	gaatccacca	ctaccagcag	tgtgtcgacc	acgccatgaa	gctgcagatg	3540
	ctgtggggag	atggtctacg	actgtctaaa	ccggcgccga	tcttgatgag	agcttacgga	3600
	tacgcccata	aaatcagcga	agccgttgtt	tcctccttaa	gcagaaagtt	ctcgtctgca	3660
5	agagtgttgc	gcccgcttgc	tgtccaccag	aatacagaag	tgtctcttgc	gttctccaac	3720
	tttgacaacg	gaaagagacc	ctctacgcta	caccagatga	ataccaagct	gagtgcctgt	3780
	tatgcccggg	aagccatgca	cacggccggg	tgtgcacccat	cctacagagt	taagagagca	3840
	gacatagcca	cgtgcacaga	agcggtctgt	gttaacgcag	ctaacgcccg	tggaaactgta	3900
	ggggatggcg	tatgcagggc	cgtggcgaag	aaatggccgt	cagcctttaa	gggagcagca	3960
10	acccagtggt	gcacaattaa	aacagtcatg	tgcggctcgt	acccgctcat	ccaagctgta	4020
	cgccctaatt	tctctgccac	gactgaagcg	gaaggggacc	gcgaattggc	cgctgtctac	4080
	cgggcagtggt	ccgcccgaagt	aaacagactg	tcactgagca	gcgttagccat	cccgctgctg	4140
	tccacaggag	tgcttcagcgg	cggaaagagat	aggtctgcagc	aatccctcaa	ccatctattc	4200
	acagcaatgt	acgcccagga	cgctgacgtg	accatctact	gcagagacaa	aagtctgggag	4260
15	aagaaatcc	aggaagccat	tgacatgagg	acggctctgtg	agttgtctaa	tgatgacgtg	4320
	gagctgacca	cagacttggt	gagagtgcac	ccggacagca	gcctgggtggg	tcgttaagggc	4380
	tacagtacca	ctgacgggtc	gctgtactcg	tactttgaag	gtacgaaatt	caacagggtc	4440
	gctattgata	tggcagagat	actgacgttg	tggcccagac	tgcaagagggc	aaacyaagac	4500
	atatgctcat	acggtctggg	cgaacaatg	gacaaacatc	gatccaaatg	tcgggtgaac	4560
20	gatctcgatt	catcaacacc	tcccaggaca	gtgcctctgc	tgtgcgcgta	cgcaatgaca	4620
	gcagaaacga	tcgcccgcct	taggtccacac	caagttaaaa	gcattggtggg	tgtgctcatc	4680
	tttccctcc	cgaataacca	tgtagatggg	gtgcagaagg	taaatgtcga	gaaggtcttc	4740
	ctgttccgac	cgacggtaac	ttcagtggtt	agtcggcgga	agttatggcg	atctacagca	4800
	gaccactcag	atcggtcgtt	acgaggggtt	gacttggact	ggaccacaga	cagctcttcc	4860
25	actgccagcg	ataccatgtc	gctacccagt	ttgcagctgt	gtgacatoga	ctcgatctac	4920
	gagccaatgg	ctcccatagt	agtgcagcgt	gacgtacacc	ctgaaccncc	agggcatcgg	4980
	gacgtggcgg	cagatgtgca	ccctgaaccc	gcagaccatg	tggacotgta	caaccggatt	5040
	ctctccaccg	gcccgaaag	agctgcatac	cttgccctccc	ggcgggcgga	gcgacgggtg	5100
	ccggcgccga	gaaagccgac	gcttgcacca	aggactgcgt	ttaggaaacaa	gctgctcttg	5160
30	acgttccggg	actttgacga	gcacagagtc	gatgcgttgg	cctccgggatt	tactttccga	5220
	gacttccgag	acgtcctcgc	actagggcgc	gggggtgcac	attttttctc	ctcgggacat	5280
	ggcagcggac	atttacaaca	aaaatccggt	agggcagaca	atctccagtg	cgccacaactg	5340
	gatcggtccc	aggagggaaa	aatgtaccgc	ccaaaattgg	atactgagag	ggagaaagctg	5400
	ttgctgctga	aaatgcagat	gcacccatcg	gaggtctaata	agagtcogata	ccagctctcg	5460
35	aaagtggaga	acatgaaagc	cacggtgggt	gacaggctca	catcggyggc	cagattgtac	5520
	acgggagcgg	acgtgaagcg	cataccaaca	tacgcygttc	ggtacccccg	ccccgtgtac	5580
	tcccctaccg	tgatcgaaag	attctcaagc	cccgatgtag	caatcgagc	gtgcaacgaa	5640
	tacctatcca	gaaattacc	aacagtggcg	tcgtaccaga	taacagatga	atcacgagca	5700
	tacttggaca	tggttgacgg	gtcggatagt	tgcttggaca	gagcgacatt	ctgcccggcg	5760
40	aaagtccggt	gctaccgcga	acatcatgcy	taccaccagc	cgactgtacy	cagtgccgtc	5820
	ccgtcaacct	ttcagaaac	actacagaac	gtgctagcgg	ccgccaccac	gagaaactgc	5880
	aaagtccagc	aaatgcgaga	actaccaccc	atggactcgg	cagtggtcaa	cgtggagtgc	5940
	ttcaagcgct	atgctctgtc	cggagaatat	tgggaagaat	atgctaaca	acctatccgg	6000
	ataaccactg	agaaatcac	tacctatgtg	accaaatgaa	agggcccgaa	agctgctgcc	6060
45	ttgttcgcta	agaccacaga	cttggttccg	ctgcaggagg	ttcccatgga	cagattcacg	6120
	gtcgacatga	aacgagatgt	caaagtcact	ccagggagca	aacacacaga	ggaaagacc	6180
	aaagtccagc	taattcaagc	agcgagagca	ttggcgacgg	cttacctgtg	cggtatccac	6240
	agggaaatca	taaggagact	aaatgctgtg	ttacgcctca	actgcacac	atttgttgat	6300
	atgtcggcgg	aagactttga	cgcgatcatc	gctctcact	tcacccaggy	agacccgggt	6360
50	ctagagacgc	acattgcatc	attcgacaaa	agccaggagc	actccttggc	tcttacaggt	6420
	ttaatgatcc	tcgaagatct	aggggtggat	cagtacctgc	tggactttgat	ggggcagccc	6480
	tttggggaaa	tatccagctg	tcacctacca	actggcagcg	gcttcaagtt	cggagctatg	6540
	atgaaatcgg	gcatgtttct	gactttgttt	attaaacactg	ttttgaacat	cacatagca	6600
	agcagggtag	tggagcagag	actcactgac	tcgcctctgt	cggccttcat	cggcgagac	6660
55	aaacatcgct	accgagtgat	ctccgacaa	ctgatggcgg	agaggtgcgc	gtcgtgggtc	6720
	aacatcgagg	tgaagatcat	tgacgctgtc	atggggcga	aaaccccata	tttttggggg	6780
	ggattcatag	tttttgacag	cgtcacacag	acgcctctgc	gtgtttcaga	ccacttaag	6840
	cgctgtcca	agttgggttaa	gccgttaaca	gctgaagaca	agcaggagca	agcaggcga	6900
	cgagcactga	gtgacagaggt	tagcaagtgg	ttccggagac	gcttgggggc	cgaactggag	6960

64460

	gtggcactaa	catctaggta	tgaggtagag	ggctgcamaa	gtatcctcat	agccatggcc	7020
	accttggcga	gggacattaa	ggcgtttaag	aaattgagag	gacctgttat	acacctctac	7080
	ggcgttccta	gattggtgcy	ttaatacaca	gaattctgat	tggatcatag	cgcactatta	7140
	taggatccag	atccccggta	attaattgaa	ttacatccct	acgcacaact	tttacggccg	7200
5	ccggtggcgc	ccgcgcgcgg	cggcccgctc	ttggccgttg	caggccactc	cgttggctcc	7260
	cgtcgtcccc	gacttccagg	cccagcagat	gcagcaactc	atcagcgccg	taaatgcgct	7320
	gacaaatgaga	cagaaocgaa	ttgctcctgc	taggcctccc	aaaccaaaga	agaagaagac	7380
	aaccaaaacca	aagccgaaaa	cgcagcccaa	gaagatcaac	ggaacaaagc	agcagcaaaa	7440
	gaagaagac	aagccagccg	acaagaagaa	gaagaacccc	ggaacaaagc	aaagaatgtg	7500
10	catgaagatt	gaaaatgact	gtatcttcgt	atgcggctag	ccacagttaac	gtagtgtttc	7560
	cagacatgtc	gggcacgcga	ctatcatggg	tgcaaaaaat	ctcgggtggg	ctgggggccc	7620
	tcycaatcgg	cgtatcctcg	gtgctgggtg	tggtcacttg	cattgggtcc	cgcagataag	7680
	ttagggtagg	caatggcatt	gatatagcna	gaaaattgaa	aacagaaaaa	gttagggtaa	7740
	gcaatggcat	ataaccataa	ctgtataact	tgtaacaaag	cgcacaaaga	cctgcgcant	7800
15	tggcccccgtg	gtccgcctca	cggaaactcg	gggcaactca	tattgacaca	ttaatgggca	7860
	ataattggaa	gcttacataa	gcttaattcg	acgaataatt	gggtttttat	tttattttgc	7920
	aatgggtttt	taattatttc	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	7980
	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	ctagcgggtc	ggcatggcat	ctccacctcc	8040
20	tcgcggtccg	acctggggcat	cgaaggagg	acgcacgtcc	actoggtagg	ctaagggaga	8100

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA 98/01064

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/86 C12N15/45 C07K14/135 C07K14/115 A61K31/70

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 96 40945 A (CONNAUGHT LAB ;LI XIAOMAO (CA); EWASYSHYN MARY E (CA); SAMBHARA SU) 19 December 1996 cited in the application see the whole document, especially page 6, lines 2-9; page 14, lines 15-21; and page 23, lines 18-23 ---	1-36
Y	WO 95 27044 A (BIOPTION AB ;LILJESTROEM PETER (SE); GAROFF HENRIK (SE)) 12 October 1995 cited in the application see the whole document, especially page 8, lines 12-22 ---	1-36
A	WO 96 17072 A (VIAGENE INC) 6 June 1996 see the whole document ---	1-36
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

03/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel: (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mandl, B

# INTERNATIONAL SEARCH REPORT

Inter. Appl. No.

PCT/CA 98/01064

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ZHOU X. ET AL.: "Self-replicating Semliki-Forest virus RNA as recombinant vaccine" VACCINE, vol. 12, no. 16, 1994, pages 1510-1514, XP002089524 cited in the application see the whole document ---	1-36
A	LILJESTROEM P. ET AL.: "A NEW GENERATION OF ANIMAL CELL EXPRESSION VECTORS BASED ON THE SEMLIKI FOREST VIRUS REPLICON" BIO/TECHNOLOGY, vol. 9, December 1991, pages 1356-1361, XP000616021 cited in the application see the whole document ---	1-36
E,L	WO 99 11808 A (CONNAUGHT LAB ;PARRINGTON MARK (CA)) 11 March 1999  cited in the application see the whole document -----	1-9,20, 23,24, 32,35,36

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 98/01064

### Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 20-30  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/01064

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9640945 A	19-12-1996	AU 695527 B	13-08-1998
		AU 6117696 A	30-12-1996
		CA 2223610 A	19-12-1996
		EP 0832253 A	01-04-1998
		US 5843913 A	01-12-1998
		US 5880104 A	09-03-1999
WO 9527044 A	12-10-1995	AU 699384 B	03-12-1998
		AU 2155795 A	23-10-1995
		CA 2184261 A	12-10-1995
		EP 0753053 A	15-01-1997
		FI 963860 A	27-09-1996
		JP 9511143 T	11-11-1997
WO 9617072 A	06-06-1996	AU 4594996 A	19-06-1996
		EP 0797679 A	01-10-1997
		US 5814482 A	29-09-1998
		US 5843723 A	01-12-1998
		US 5789245 A	04-08-1998
WO 9911808 A	11-03-1999	NONE	